ArticleHeadache2020
Delay in OnabotulinumtoxinA Treatment During the COVID-19 Pandemic-Perspectives from a Virus Hotspot.
Article in Headache, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Impact of delaying botulinum toxin treatment in patients with migraine during the COVID-19 pandemic.Arquivos de neuro-psiquiatria · 2023Article
- COVID-19 effect on perioperative findings of flexible/semi-rigid ureterorenoscopic lithotripsy: A match-pair analysis.Urologia · 2023Article
- Post-COVID Headache: A Literature Review.Current pain and headache reports · 2022Review
- It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine.Arquivos de neuro-psiquiatria · 2022Article
- [Adaptation of headache units in Andalusia to the COVID-19 pandemic. Analysis of the Andalusian Neurology Society's Headache Study Group].Revista de neurologia · 2022Observational
- COVID-19-related delays of botulinum toxin injections have a negative impact on the quality of life of patients with dystonia and spasticity: a single-center ambulatory care study.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
- Impact of COVID-19 pandemic on migraine management in the United States: insights from migraine tracking app users.BMC neurology · 2021Article
- Impact and Challenges of the COVID-19 Pandemic on Patients Requiring Botulinum Toxin A Treatment.Journal of movement disorders · 2021Article
- Hospital-based headache care during the Covid-19 pandemic in Denmark and Norway.The journal of headache and pain · 2020Article
- Headache as the Presenting Symptom in 2 Patients With COVID-19 and a History of Migraine: 2 Case Reports.Headache · 2020Article
- Should We Adapt the Prescription Criteria for Specific Treatments for Migraine Due to the COVID-19 Pandemic?Headache · 2020Article
- Observational
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has undoubtedly changed our practice of medicine. With our collective resources and attention focused on caring for those afflicted with the disease, other medical conditions have temporarily but understandably faced constraint. For migraine patients who often require in-person visits for infusions and procedures, this has become particularly challenging. Here, we share our experience in navigating this exigency amidst a local surge of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.